

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI735877

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	01/02/2025
CONVEYING PARTY DATA	
Name	Execution Date
ARIAD Pharmaceuticals, Inc.	12/24/2024
RECEIVING PARTY DATA	
Company Name:	Takeda Pharmaceuticals U.S.A., Inc.
Street Address:	500 Kendall Street
City:	Cambridge
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 21	
Property Type	Number
Application Number:	11644849
Application Number:	13357745
Application Number:	13801116
Application Number:	13801619
Application Number:	14296016
Application Number:	14651577
Application Number:	15341898
Application Number:	16146143
Application Number:	16465073
Application Number:	16469517
Application Number:	16881790
Application Number:	17226531
Application Number:	17318677
Application Number:	17318772
Application Number:	17318832
Application Number:	17318876
Application Number:	17498796
Application Number:	18175272
Application Number:	18361430

Property Type	Number
Application Number:	18654459
Application Number:	18763056

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6176797000

Email: ipdocketing@takeda.com

Correspondent Name: Constance Yeung

Address Line 1: 500 Kendall Street

Address Line 2: 4th Floor

Address Line 4: Cambridge, MASSACHUSETTS 02139

NAME OF SUBMITTER:	Nora Ubinas
SIGNATURE:	Nora Ubinas
DATE SIGNED:	01/07/2025
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 3

source=ARIAD Pharmaceuticals Inc.-DE-Merger (Discontinuing Company)#page1.tiff

source=ARIAD Pharmaceuticals Inc.-DE-Merger (Discontinuing Company)#page2.tiff

source=ARIAD Pharmaceuticals Inc.-DE-Merger (Discontinuing Company)#page3.tiff

Delaware


The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"ARIAD PHARMACEUTICALS, INC.", A DELAWARE CORPORATION, WITH AND INTO "TAKEDA PHARMACEUTICALS U.S.A., INC." UNDER THE NAME OF "TAKEDA PHARMACEUTICALS U.S.A., INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTY-SIXTH DAY OF DECEMBER, A.D. 2024, AT 10:18 O`CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE SECOND DAY OF JANUARY, A.D. 2025.



A handwritten signature in black ink, appearing to read "JB", is written over a horizontal line. Below the line, the text "Jeffrey W. Bullock, Secretary of State" is printed.

2894153 8100M
SR# 20244603816

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 205231680
Date: 12-26-24

PATENT
REEL: 069769 FRAME: 0322

State of Delaware
Secretary of State
Division of Corporations
Delivered 10:18 AM 12/26/2024
FILED 10:18 AM 12/26/2024
SR 20244603816 - File Number 2894153

CERTIFICATE OF MERGER

of

ARIAD Pharmaceuticals, Inc.
(a Delaware corporation)

with and into

Takeda Pharmaceuticals U.S.A., Inc.
(a Delaware corporation)

Pursuant to Section 251 of the General Corporation Law of the State of Delaware (the “DGCL”), Takeda Development Center Americas, Inc., a Delaware corporation, does hereby certify:

FIRST: That the name and state of incorporation of each of the constituent corporations are as follows:

<u>Name</u>	<u>State of Incorporation</u>
ARIAD Pharmaceuticals, Inc.	Delaware
Takeda Pharmaceuticals U.S.A., Inc.	Delaware

SECOND: That an Agreement of Merger (the “Merger Agreement”) pursuant to which ARIAD Pharmaceuticals, Inc., a Delaware corporation, will merge with and into Takeda Pharmaceuticals U.S.A., Inc. (the “Merger”) has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Section 251 of the DGCL.

THIRD: That Takeda Pharmaceuticals U.S.A., Inc. shall be the surviving corporation (the “Surviving Corporation”).

FOURTH: That the Certificate of Incorporation of the Surviving Corporation as in effect immediately prior to the effective date of the Merger shall be the Certificate of Incorporation of the surviving corporation.

FIFTH: That the executed Merger Agreement is on file at the office of the Surviving Corporation, the address of which is 500 Kendall Street, Cambridge, MA 02142.

SIXTH: That a copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of any constituent corporation.


SEVENTH: That this Certificate of Merger and the Merger shall become effective as of January 2, 2025.

EIGHTH: It is intended that the Merger constitute a reorganization within the meaning of Section 368(a)(1) of the Internal Revenue Code of 1986, as amended, and the agreements, instruments or ancillary documents relating to the Transaction, together are intended to constitute a plan of reorganization within the meaning of Treas. Reg. § 1.368-2(g)

(Signature page follows)

IN WITNESS WHEREOF, the Surviving Corporation has caused this Certificate of Merger to be signed by a duly authorized officer, declaring that the facts stated herein are true.

TAKEDA PHARMACEUTICALS U.S.A., INC.

DocuSigned by:

By: _____
Name: Max Heuer
Title: Assistant Secretary
Date: 24-Dec-2024 | 20:02 JST

Signature Page to Certificate of Merger